Zimmer Biomet forecasts 2025 profit below estimates
Medical device maker Zimmer Biomet Holdings forecast full-year adjusted profit below Wall Street estimates on Thursday, as it anticipates a hit from a strong dollar. The company expects 2025 adjusted profit to be in the range of $8.
Zimmer Biomet: Adding To The Growth Profile
Zimmer Biomet shares at $105 reveal value at 13 times adjusted earnings, as the company continues to grow despite a GLP-1 drug overhang. Explore more details here.
Why Is Zimmer Biomet Stock Trading Lower On Thursday?
Zimmer Biomet Holdings, Inc (NYSE:ZBH) reported fourth-quarter adjusted EPS of $2.31, up from $2.20 a year ago, beating the Street estimates of $2.30. The orthopedic giant reported sales of $2.02 billion,
Which Is a Better Investment, IDEXX Laboratories, Inc. or Zimmer Biomet Holdings, Inc. Stock?
Learn more about whether IDEXX Laboratories, Inc. or Zimmer Biomet Holdings, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.
Zimmer Biomet Holdings Inc. stock underperforms Thursday when compared to competitors
Shares of Zimmer Biomet Holdings Inc. ZBH slipped 5.14% to $102.69 Thursday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500 Index SPX rising 0.36% to 6,083.57 and the Dow Jones Industrial Average DJIA falling 0.28% to 44,747.63.
Zimmer Biomet price target lowered to $113 from $118 at Truist
Truist analyst Richard Newitter lowered the firm’s price target on Zimmer Biomet (ZBH) to $113 from $118 and keeps a Hold rating on the shares.
Zimmer Biomet Holdings Inc. stock underperforms Friday when compared to competitors
Shares of Zimmer Biomet Holdings Inc. ZBH shed 1.71% to $100.93 Friday, on what proved to be an all-around rough trading ...
Zimmer Biomet to buy Paragon 28 for $1.1 billion
Zimmer Biomet said on Tuesday it would acquire medical device company Paragon 28 for about $1.1 billion to expand its ...
Zimmer Biomet price target lowered to $112 from $118 at Barclays
Barclays lowered the firm’s price target on Zimmer Biomet (ZBH) to $112 from $118 and keeps an Underweight rating on the shares. The firm ...
Zimmer Biomet Snaps Up Paragon 28 In $1.2 Billion Deal: Details
Zimmer Biomet agrees to acquire Paragon 28 for $1.1 billion, with a non-tradeable CVR up to $1 per share. Deal expected to ...
MassDevice4d
Zimmer Biomet beats The Street in Q4
Zimmer Biomet (NYSE: ZBH) shares dipped slightly today on fourth-quarter results that came in just ahead of the consensus ...
Zimmer Biomet slips as outlook misses consensus
Despite reporting better-than-expected Q4 2024 results, shares of Zimmer Biomet (NYSE:ZBH) fell in the morning hours Thursday after the orthopedic device maker set its 2025 outlook below consensus.